<sup>99</sup>Tc<sup>m</sup>-MIBI显像在乳腺癌新辅助化疗中的应用价值

陈伟君; 孙达; 陈伟君; 孙达

doi:10.3760/cma.j.issn.1673-4114.2015.06.011

[1]

夏晓天, 张永学.影像学检查在乳腺癌的诊断及疗效评估中的应用价值[J].国际放射医学核医学杂志, 2010, 34(4):242-246. doi: 10.3760/cma.j.issn.1673-4114.2010.04.014

[2]

Kolesnikov-Gauthier H, Vanlemmens L, Baranzelli MC, et al. Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG-PET after the first course[J]. Breast Cancer Res Treat, 2012, 131(2):517-525. doi: 10.1007/s10549-011-1832-4

[3]

董佳佳, 章斌.多种影像学方法评价乳腺癌新辅助化疗疗效的价值比较[J].国际放射医学核医学杂志, 2014, 38(6):427-432.

[4]

Sun Y, Wei W, Yang HW, et al. Clinical usefulness of breast-specific gamma imaging as an adjunct modality to mammography for diagnosis of breast cancer:a systemic review and meta-analysis[J]. Eur J Nucl Med Mol Imaging, 2013, 40(3):450-463. doi: 10.1007/s00259-012-2279-5

[5]

谭辉, 张一秋, 石洪成.核医学乳腺专用显像仪在乳腺癌诊疗中的应用[J].中华核医学与分子影像杂志, 2014, 34(1):73-75. doi: 10.3760/cma.j.issn.2095-2848.2014.01.024

[6]

孙达, 陈伟君.乳腺专用伽玛显像(BSGI)技术的最新进展[J].中国医疗器械杂志, 2015, 39(2):108-112. doi: 10.3969/j.issn.1671-7104.2015.02.009

[7]

Sergieva SB, Timcheva KV, Hadjiolov ND. ^99mTc-MIBI scintigraphy as a functional method for the evaluation of multidrug resistance in breast cancer patients[J]. J BUON, 2006, 11(1):61-68.

[8]

Mankoff DA, Dunnwald LK, Gralow JR, et al. Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using[Technetium 99m]-sestamibi scintimammography[J]. Cancer, 1999, 85(11):2410-2423. doi: 10.1002/(SICI)1097-0142(19990601)85:11<2410::AID-CNCR16>3.0.CO;2-K

[9]

Spanu A, Farris A, Chessa F, et al. Planar scintimammography and SPECT in neoadjuvant chemo or hormonotherapy response evaluation in locally advanced primary breast cancer[J]. Int J Oncol, 2008, 32(6):1275-1283.

[10]

Fuster D, Muñoz M, Pavia J, et al. Quantified ^99mTc-MIBI scintigraphy for predicting chemotherapy response in breast cancer patients:factors that influence the level of ^99mTc-MIBI uptake[J]. Nucl Med Commun, 2002, 23(1):31-38.

[11]

Novikov SN, Kanaev SV, Petr KV, et al. Technetium-99m methoxyisobutylisonitrile scintimammography for monitoring and early prediction of breast cancer response to neoadjuvant chemotherapy[J]. Nucl Med Commun, 2015, 36(8):795-801. doi: 10.1097/MNM.0000000000000331

[12]

Listewnik MH, Birkenfeld B, Foszczyńska-Kłoda M, et al. Response of malignant breast tumours to neoadjuvant chemotherapy evaluated with Tc-99m MIBI[J]. Ann Acad Med Stetin, 2011, 57(1):73-78.

[13]

贾莉, 邹天宁, 夏正武, 等. ^99mTc-MIBI乳腺显像评价乳腺癌新辅助化疗效果的临床价值[J].现代医学, 2014, 42(1):4-8.

[14]

Tiling R, Linke R, Untch M, et al. ¹⁸F-FDG PET and ^99mTc-sestamibi scintimammography for monitoring breast cancer response to neoadjuvant chemotherapy:a comparative study[J]. Eur J Nucl Med, 2001, 28(6):711-720.

[15]

Si H, Li X. Abundant blood supply and low P-glycoprotein expression on dynamic ^99mTc-MIBI imaging predicted better chemotherapy sensitivity for a breast cancer patient:a case report[J]. J Nucl Med Technol, 2012, 40(2):89-91.

[16]

Dizdarevic S, Peters AM. Imaging of multidrug resistance in cancer[J]. Cancer Imaging, 2011, 11(11):1-8.

[17]

Mubashar M, Harrington KJ, Chaudhary KS, et al. ^99mTc-sestamibi imaging in the assessment of toremifene as a modulator of multidrug resistance in patients with breast cancer[J]. J Nucl Med, 2002, 43(4):519-525.

[18]

贾莉, 邹天宁, 夏正武, 等. ^99mTc-MIBI显像预测乳腺癌新辅助化疗疗效的临床应用[J].临床医学, 2013, 33(11):18-20. doi: 10.3969/j.issn.1003-3548.2013.11.008

[19]

刘文峰, 墙华, 杨晓君, 等. 99m锝-甲氧基异丁基异腈显影预测乳腺癌新辅助化疗疗效的应用研究[J].宁夏医学杂志, 2010, 32(8):693-694. doi: 10.3969/j.issn.1001-5949.2010.08.008

[20]

张雪梅, 刘志军, 杨秀蓉. ^99mTc-MIBI显像可预测乳腺癌新辅助化疗的反应性[J].生物医学工程与临床, 2006, 10(5):290-292, 335. doi: 10.3969/j.issn.1009-7090.2006.05.006

[21]

刘真真, 卢振铎, 张恒伟, 等. ⁹⁹Tc^m-甲氧基异丁基异腈显像对可手术乳腺癌新辅助化疗疗效的预测价值[J].中华肿瘤杂志, 2011, 33(7):544-546. doi: 10.3760/cma.j.issn.0253-3766.2011.07.016

[22]

袁超, 李卫鹏. ⁹⁹Tc^m-tetrofosmin:一种评价体内P-糖蛋白功能变化的显像剂[J].国际放射医学核医学杂志, 2009, 33(3):144-148. doi: 10.3760/cma.j.issn.1673-4114.2009.03.005

[23]

Del Vecchio S, Ciarmiello A, Pace L, et al. Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients[J]. J Nucl Med, 1997, 38(9):1348-1351.

[24]

Cayre A, Cachin F, Maublant J, et al. Single static view ^99mTc-sestamibi scintimammography predicts response to neoadjuvant chemotherapy and is related to MDR expression[J]. Int J Oncol, 2002, 20(5):1049-1055.

[25]

杨晓君, 王惠, 余建军.乳腺癌99m锝-甲氧基异丁基异腈显像与三种多药耐药蛋白表达的关系[J].宁夏医学杂志, 2009, 31(8):681-683. doi: 10.3969/j.issn.1001-5949.2009.08.004

[26]

崔树德, 刘真真, 刘慧, 等.甲氧基乙丁基异腈亲肿瘤显像与乳腺癌多药耐药类蛋白关系的研究[J].中华肿瘤杂志, 2005, 27(10):606-608. doi: 10.3760/j.issn:0253-3766.2005.10.008

[27]

林开文, 刘保平, 程兵.乳腺癌⁹⁹Tc^m-MIBI显像与P-gp、MRP表达的关系[J].中华核医学杂志, 2005, 25(5):40-42,75.

[28]

Kao CH, Tsai SC, Liu TJ, et al. P-Glycoprotein and multidrug resistance-related protein expressions in relation to technetium-99m methoxyisobutylisonitrile scintimammography findings[J]. Cancer Res, 2001, 61(4):1412-1414.

[29]

Takamura Y, Miyoshi Y, Taguchi T, et al. Prediction of chemotherapeutic response by Technetium 99m-MIBI scintigraphy in breast carcinoma patients[J]. Cancer, 2001, 92(2):232-239.

[30]

Kostakoglu L, Ruacan S, Ergün EL, et al. Influence of the heterogeneity of P-glycoprotein expression on technetium-99m-MIBI uptake in breast cancer[J]. J Nucl Med, 1998, 39(6):1021-1026.